Neuren Pharmaceuticals’ (ASX:NEU) drug to treat Rett syndrome gets US FDA approval; shares up 20%

March 13, 2023 12:48 PM AEDT | By Priyabrata Prusty
Follow us on Google News:


  • NEU shares jumped over 20% in early morning trade on Monday.
  • The US drug regulator has approved its compound trofinetide for treating Rett syndrome.
  • Neuren will receive milestone payments and royalties on the sale of the drug from its North American partner Acadia Pharmaceuticals.

ASX biotech company Neuren Pharmaceuticals' (ASX:NEU) shares skyrocketed on Monday, 13 March 2023, as its compound trofinetide got the US Food and Drug Administration’s (FDA) approval for the treatment of Rett syndrome.

As of 10:50 am, AEDT NEU shares traded 19.426% higher at AU$9.160, after touching an intraday high of AU$9.740.

In an ASX announcement, Neuren Pharmaceuticals today said its North American partner Acadia Pharmaceuticals (NASDAQ: ACAD) received the US drug regulator's approval for trofinetide for treating Rett syndrome, which is a rare neurological disorder that emerges in infancy. DAYBUE is the brand name given to trofinetide, the first drug for the treatment of Rett syndrome.  

DAYBUE is expected to be available in the US by the end of next month.


Acadia conducted a phase 3 trial known as LAVENDER to study the efficacy and safety of trofinetide in 187 female patients between five to 20 years of age with Rett syndrome. After the study showed positive results, it was sent to the US FDA for its approval.

Now, with the FDA approval for DAYBUE, Acadia has received a Rare Pediatric Disease Priority Review Voucher (PRV). This  PRV can be used to obtain priority review for a subsequent application, the company said.

Acadia entered into an exclusive license agreement in 2018 with Neuren for developing and commercialising trofinetide in North America, while Neuren retains the rights for all countries outside North America. Neuren intends to pursue registration and commercialisation of trofinetide through partners and is currently advancing discussions with a number of third parties.

Neuren Pharmaceuticals’ revenue outlook

Neuren will receive a milestone payment of US$40 million from Acadia after the first commercial sale of trofinetide in the United States. This is expected by the end of next month. The company received a milestone payment of US$10 million in October last year from Acadia after NDA was accepted for FDA review.

Neuren will also receive royalties on net sales of trofinetide in North America, plus milestone payments of up to US$350 million on achievement of a series of four thresholds of total annual net sales, plus one-third of the market value of the PRV, which was awarded to Acadia by the FDA upon approval of the NDA.

As per Neuren’s estimates, the value of the one-third share of PRV is likely to be around US$33 million. Also, Neuren is not required to pay any royalties or similar costs to third parties. This means Neuren’s revenue from Acadia will be directly added to pre-tax profit. The royalty rates and sales milestone payments are related to the total amount of annual net sales of trofinetide.


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK